| Identification | Back Directory | [Name]
4-(1H-PYRAZOL-4-YL)-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE | [CAS]
941685-27-4 | [Synonyms]
CS-1703
INCB032304
RROLO[2,3-D]PYRIMIDINE
-7-((2-(trimethylsilyl)
Barretinib Intermediate 1
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl-7H-p...
4-(1H-pyrazol-4-yl)-7-((2-trimethylsilanylethoxy)methyl)-7H-pyrrolo[2,3-d]p
4-(4-Pyrazolyl)-7-[[2-(trimethylsilyl)ethoxy]methyl]-7H-pyrrolo[2,3-d]pyrimidine
(1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
rimethyl-[2-[[4-(1H-pyrazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]methoxy]ethyl]silane
trimethyl-[2-[[4-(1H-pyrazol-4-yl)pyrrolo[2,3-d]pyrimidin-7-yl]methoxy]ethyl]silane
4-(1H-pyrazol-4-yl)-7-((2-trimethylsilanylethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
4-(1H-PYRAZOL-4-YL)-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE
4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole
7H-Pyrrolo[2,3-d]pyrimidine, 4-(1H-pyrazol-4-yl)-7-[[2-(trimethylsilyl)ethoxy]methyl]-
4- (1H pyrazole-4-yl) -7- (2- (trimethylsilyl) ethoxy) - methyl) -7H pyrrolo [2,3-d] pyrimidine
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidineQ: What is
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine Q: What is the CAS Number of
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine Q: What is the storage condition of
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine | [EINECS(EC#)]
801-232-2 | [Molecular Formula]
C15H21N5OSi | [MDL Number]
MFCD11857754 | [MOL File]
941685-27-4.mol | [Molecular Weight]
315.451 |
| Chemical Properties | Back Directory | [Boiling point ]
501.8±50.0 °C(Predicted) | [density ]
1.20±0.1 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [form ]
solid | [pka]
10.87±0.50(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C15H21N5OSi/c1-22(2,3)7-6-21-11-20-5-4-13-14(12-8-18-19-9-12)16-10-17-15(13)20/h4-5,8-10H,6-7,11H2,1-3H3,(H,18,19) | [InChIKey]
AVMLPTWVYQXRSV-UHFFFAOYSA-N | [SMILES]
C1=NC(C2=CNN=C2)=C2C=CN(COCC[Si](C)(C)C)C2=N1 |
| Hazard Information | Back Directory | [Uses]
4-(1H-Pyrazol-4-yl)-7-[[2-(trimethylsilyl)ethoxy]methyl]-7H-pyrrolo[2,3-d]pyrimidine is an important intermediate in the preparation of the janus kinase inhibitor INCB018424. | [Chemical Properties]
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine is a solid, it is incompatible with strong oxidizing agents.
| [Synthesis]
To a flask equipped was added 4-chloro-7-(2-trimethylsilanylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine and dioxane and then added 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole followed by a solution of potassium carbonate in water. The solution was degassed by passing a stream of nitrogen through the solution for 15 minutes before being treated with tetrakis(triphenylphosphine)palladium(0), and the resulting reaction mixture was heated at reflux (about 90° C) for 2 hours. When the reaction was complete, the mixture was cooled to room temperature and diluted with ethyl acetate and water. The two layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over sodium sulfate (Na2SO4), and concentrated under reduced pressure. The residue was suspended in toluene, and the solvent was removed under reduced pressure. The residue was finally triturated with methyl tert-butyl ether, and the solid was collected by filtration and washed with MTBE to afford 4-(1H-pyrazol-4-yl)-7-(2-trimethylsilanyl-ethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine (yield 64%) as white crystalline solids.
![4-(1H-PYRAZOL-4-YL)-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE](/NewsImg/2023-11-16/6383572697194131121463128.jpg "4-(1H-PYRAZOL-4-YL)-7-((2-(TRIMETHYLSILYL)ETHOXY)METHYL)-7H-PYRROLO[2,3-D]PYRIMIDINE") | [Toxicity evaluation]
4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine has acute oral toxicity, it is harmful if swallowed.
| [References]
[1] Patent: US2010/190981, 2010, A1. Location in patent: Page/Page column 75-76
[2] Patent: EP3360878, 2018, A1. Location in patent: Paragraph 0140; 0145
[3] Patent: WO2016/35014, 2016, A1. Location in patent: Page/Page column 27 |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS07 | [Signal word ]
Warning | [Hazard statements ]
H302 | [Precautionary statements ]
P280-P305+P351+P338 | [Hazard Codes ]
Xn | [Risk Statements ]
22 | [WGK Germany ]
WGK 3 | [REACH Registrations]
Active | [HazardClass ]
IRRITANT | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral |
|
| Company Name: |
Harway Pharma CO., LTD Gold
|
| Telephone: |
18254622207 18860615010 |
| Website: |
http://www.harwaypharma.com |
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
|